This article has been updated from a previous version as Qiagen clarified an earlier statement regarding its acquisition of PrimeraDx.

NEW YORK (GenomeWeb) — Qiagen said today that it is collaborating with Eli Lilly to co-develop universal and modular assay panels to simultaneously analyze DNA and RNA biomarkers targeting multiple cellular pathways in common cancer types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.